about
Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis.Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout miceHaematuria increases progression of advanced proteinuric kidney disease.TWEAK and Fn14. New players in the pathogenesis of atherosclerosis.TWEAKing renal injury.A slit in podocyte death.Considering TWEAK as a target for therapy in renal and vascular injury.NF-kappaB in renal inflammation.Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK.AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences.Haematuria: the forgotten CKD factor?Targeting chemokines in proteinuria-induced renal disease.Role of chemokines in proteinuric kidney disorders.Translational value of animal models of kidney failure.Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms.The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB.Two independent apolipoprotein A5 haplotypes modulate postprandial lipoprotein metabolism in a healthy Caucasian population.Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury.The influence of the apolipoprotein E gene promoter (-219G/ T) polymorphism on postprandial lipoprotein metabolism in young normolipemic males.Podocytes are new cellular targets of haemoglobin-mediated renal damage.In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosisPeripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma RatioApoptosis in the KidneyGlomerular Hematuria: Cause or Consequence of Renal Inflammation?Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic OpportunitiesPathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
P50
Q31152445-C9852A3A-C660-4666-875E-5880AA2A2DEEQ33419937-00B868B4-06C8-4F23-9FE5-AEF5B88879DBQ35080598-4E04BF89-51E9-4562-A9D7-C6FA8120C33EQ35643248-CA55E198-3411-49ED-BCA1-CFB5B87633D2Q36813819-B363E788-AD3C-4F72-9E57-41EFFDB6B87EQ36991865-9500E8E1-F1E5-414F-B6F9-30BB03ACC857Q37232965-BE2B0186-E808-49F9-9A4A-7D77CAEBA98FQ37501679-08D20A42-08BF-4B35-9F9A-D5155DA864D6Q37774798-2F03265F-1BBE-4F55-9BBF-50F82BF4EF81Q37871569-A1982B6E-DDAC-4B6E-A0FA-73488CF2E6C7Q37957837-7C871838-4EA7-403C-829C-36BA7B30D945Q37979775-FC7DABC6-BB8A-46EB-9AB3-A18B3F0473FDQ38026076-79274D97-ECAA-477A-8F37-91C4A8FD3266Q38188747-657B082C-A2E5-4116-A052-8C8DC8B08072Q38392816-3ED1A1DE-44F0-4720-AD5D-A7074DAAC415Q38985548-40A2CFCA-5E34-4A7D-B785-9E2548164C0DQ39515008-8D7FBCFA-181F-4756-82A7-76FBC5CC974DQ42170225-39F2012F-7B2F-422A-9B29-3BA05BAF8272Q42937270-4F41E299-7468-4298-B1B6-2E2F5113D68DQ44552204-E266C077-AC9C-407B-970A-E688CFFA2EABQ47330519-BA6B95A8-0ED6-4EFF-8791-5D3E25C2CE09Q57243353-9F0D2224-9DEB-445C-9E51-CA1916878CAEQ57767325-D4D254BF-632B-4384-8F55-017EF1FC5BE1Q63684379-06165FFA-633B-4D1A-A094-FF10EAFC4700Q64992038-1B231D55-444F-4E22-A1BD-B02EBDD8416BQ91920669-D50BE9C5-70F9-436B-83FD-0CE026368390Q96019963-3E9B9F75-CB01-43DC-ACD6-F3986A65D7CB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juan A Moreno
@ast
Juan A Moreno
@en
Juan A Moreno
@es
Juan A Moreno
@nl
Juan A Moreno
@sl
type
label
Juan A Moreno
@ast
Juan A Moreno
@en
Juan A Moreno
@es
Juan A Moreno
@nl
Juan A Moreno
@sl
altLabel
Juan Antonio Moreno Gutierrez
@en
prefLabel
Juan A Moreno
@ast
Juan A Moreno
@en
Juan A Moreno
@es
Juan A Moreno
@nl
Juan A Moreno
@sl
P106
P21
P31
P496
0000-0002-7468-2871